News

Oxford Biomedica Confirms Aura Biosciences Partnership For Phase 3 Eye Cancer Drug Manufacturing

NASDAQ

(RTTNews) - Oxford Biomedica plc (OXB.L), a gene and cell therapy company, on Tuesday confirmed its manufacturing and supply partnership with Aura Biosciences, Inc. (AURA), a biotechnology company.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.